Introduction 33 Bipolar disorder (BD) is a common psychiatric illness characterized by prominent mood swings with 34 episodes of mania and depression. BD is the 6th leading cause of disability among adolescents and 35 young adults (1) -without treatment, 15% of BD patients commit suicide (2). Since its introduction 36 by John Cade in 1949 (3) , lithium has remained the single most effective treatment for BD (4). The 37 discovery of lithium's effect on mania was purely accidental. Based on the misconception that there 38 was some connection between mania and urea, John Cade injected uric acid into guinea pigs and 39 used lithium urate as a solubilization agent. To his surprise, this produced a calming effect, instead 40 of the predicted excitement. Through a series of carefully controlled experiments, Cade was able to 41 identify the lithium salt as the active compound. He administered lithium to 10 manic patients who 42 responded remarkably well (3), a breakthrough that signaled the discovery of the first effective drug 43 to treat mental illness. Meta-analysis of randomized controlled trials have since shown that lithium is 44 effective against both the manic and depressive phases of BP -lithium reduces the risk of manic 45 relapses by 38% and depressive relapses by 28% (5). The drug also decreases the risk of suicide in 46 patients with mood disorders by more than 50% (6). However, only a fraction of BP patients respond 47 to lithium and the drug suffers from low therapeutic index and adverse side effects (weight gain, 48 possible renal dysfunction), creating an unmet need for better mood stabilizers. Moreover, despite 49 the use of lithium in the clinic for more than 50 years, its mechanism of action is poorly understood. 50 Several molecular targets have been identified -Gsk3 (7), inositol phosphatase (8), CRMP2 (9), 51 TrkB (10), and Protein kinase C (11) -but it is not clear how these proteins and pathways 52 contribute to BD pathogenesis. The difficulty in assigning a mechanism of action for lithium is linked 53 to our poor understanding of BD's etiology. Increasing evidence, however, points to glutamate 54 hyperexcitability as a central feature of this mental condition. Functional imaging studies show 55 widespread increase in combined glutamate and glutamine levels in the brain of BD patients (12,13) 56 and elevated glutamate levels have also been reported in prefrontal cortex of BD postmortem brains 57 (14) . Perturbed glutamate neurotransmission in BD is further supported by several imaging and 58 postmortem studies describing altered levels of postsynaptic glutamate receptors. Notably, induced 59 pluripotent stem cells (iPSCs)-derived hippocampal neurons from BD patients are hyperexcitable 60 (15), a phenotype which is selectively reversed by lithium in neurons from patients that respond to 61 lithium therapy (15). Consistent with a role in reducing glutamatergic neurotransmission, lithium 62 protects against excitotoxicity by inhibiting NMDA receptors (16) and its antimanic effect is mediated 63 by BDNF/TrkB-dependent synaptic removal of AMPA receptors, at least in a mouse model of 64 hyperactivity (10). While several studies have demonstrated a role of lithium in dampening the 65 activity of postsynaptic glutamate receptors, comparatively little is known about the effect of lithium 66 on presynaptic function. Here, we investigate the impact of lithium on synaptic vesicle (SV) exo-and 67 endocytosis at individual presynaptic terminals of hippocampal neurons using an imaging assay 68 based on pHluorin (17) fused to the glutamate transporter VGlut1 (vGpH) (18). We show that lithium 69 slows down SV exocytosis, but does not alter rates of SV endocytosis during electrical stimulation. 70
Lithium decreases, however, rates of SV reuptake post-stimulation suggesting distinct modalities of 71 SV endocytosis during and after action potential (AP) firing. Collectively, our findings show that 72 lithium alters the kinetics of SV cycling at excitatory synapses, an effect expected to decrease 73 glutamatergic neurotransmission, particularly during bursts of high frequency firing. These results 74 identify the SV cycling machinery as a functional target of lithium and highlight a novel mechanism 75 by which lithium may counterbalance elevated glutamate neurotransmission in BD patients. 76
Results

77
We used the synaptic reporter vGpH (18) to examine the effect of lithium on presynaptic function in 78 hippocampal neurons. vGpH consists of the super-ecliptic pHluorin (17) fused into the first lumenal 79 loop of the VGlut1 transporter (18, 19) . In this configuration, pHluorin faces the acidic lumen of SVs 80 and its fluorescence is quenched in resting neurons. During action potentials (APs), exocytosis of 81 (Figure 1d ), a behavior consistent with previous 100 reports (19, 22, 23) . 101
We measured SV rates from an average vGpH trace generated for each FOV. Six to thirteen 102
FOVs were analyzed for each treatment and three SV cycling parameters were measured: SV exo 103 and endo rates during stimulation and time constant for SV endocytosis post-stimulation ( Figure 1f -104 h). We used different time windows to fit the exo-and endo traces during AP firing based on the 105 shape of these traces (Figure 1f ,g) so exo and endo rates are not directly comparable to each other. 106
Neurons incubated with 5mM LiCl for 24h -a concentration within the therapeutic range 107 (24) -showed a 28% decrease in SV exo rates (p = 0.036, Mann-Whitney U test) compared to 108 control cells (Figure 2a ). Lithium has no apparent effect of SV endo rates during stimulation ( Figure  109 2b), but appears to slow down SV uptake post-stimulation as reflected by an increase in the 110 endocytic time constant (Figure 2c , p = 0.13, Mann-Whitney U test), although the p-value is above 111 the 5% cutoff after correction for multiple hypothesis testing (see methods). Longer (48h-72h) 112 exposure to lithium exacerbated these effects, with a 31% reduction in SV exo rates (Figure 2d What is the mechanism by which lithium slows down SV endocytosis post-stimulation? Two 189 mechanisms of SV retrieval co-exist at nerve terminals; clathrin-mediated endocytosis (CME) which 190 is dominant during low-intensity stimulation (25), and activity-dependent bulk endocytosis (ADBE), 191 which is predominantly engaged during high-intensity stimulation (30). Interestingly, ADBE is 192 regulated by Gsk3β, a serine/threonine kinase previously implicated in BD and a major target of 193 lithium (7). A group of endocytosis proteins (the dephosphins) are dephosphorylated by calcineurin 194 during stimulation and need to be rephosphorylated after stimulation for efficient recycling of SVs. 195
One of these proteins, dynamin-1, is rephosphorylated by Gsk3β and its priming kinase cdk5 (31), a 196 phosphorylation event which is both necessary and sufficient for ADBE . Because lithium inhibits 197
Gsk3β, blockage of ADBE could be one mechanism by which this mood stabilizer slows down SV 198 endocytosis post-stimulation. 199
In addition to its role in SV retrieval, lithium also decreases rates of SV exocytosis by ~ 30%. 200
How lithium impacts SV release remains unknown, but we can exclude an effect of the drug on the 201 SV releasable pool since the vGpH signal reached the same plateau after bafilomycin treatment in 202 control and lithium-treated cells, albeit with different kinetics (Figure 3a,d) . Given the strong 203 dependence of SV exocytosis on Ca 2+ concentration, it is possible that lithium reduces Ca 2+ influx 204 and/or increases buffering of intracellular Ca 2+ in the terminal. The N-type voltage operated Ca 2+ 205 channel Cav2.2 is the major source of AP-induced Ca 2+ influx in presynaptic terminals of 206 hippocampal neurons (19,23). Of note, Cav2.2 current density is enhanced by CRMP-2 (32), a 207 phosphoprotein regulated by Gsk3β (33) and abnormally phosphorylated in iPSC-derived neurons 208 from lithium-responsive BD patients (9). Thus, lithium could function through CRMP-2 to reduce 209 Cav2.2-mediated Ca 2+ entry and, consequently, slow down SV exocytosis. 210
This study further highlights the existence of functionally distinct types of synaptic terminals 211 based on their response to lithium. We classified synaptic boutons based on the effect of lithium on 212 SV endocytosis post-stimulation. The fraction of lithium non-responders is variable (20% to 50%) 213 and is reminiscent of BD patients that don't respond to lithium treatment. The mechanism underlying 214 differential responses of synaptic boutons to lithium is likely to involve distinct modes of SV retrieval. 215
It will be interesting to compare SV cycling and lithium sensitivity in iPSC-derived neurons from both 216 lithium responsive and lithium non-responsive BD patients. 217
Finally, this study contradicts earlier work reporting no effect of acute and chronic lithium 218 treatment on SV cycling in hippocampal neurons (34). Several reasons could underlie this important 219 discrepancy. First, our measurements are done at 36.5°C rather than room temperature -it is 220 known that the kinetics of SV exocytosis and retrieval are significantly different at physiological 221 temperature (26). Second, Lueke were grown on poly-L-lysine coated glass coverslips (2.5 mm diameter) on top of (but with no direct 243 contact with) a glial feeder layer. Neurons were electroporated with vGpH immediately after 244 dissociation using the Nucleofector kit (Amaxa Biosystems, Lonza) and were imaged 14-16 days 245 after plating. 246
247
Live-cell imaging and field stimulation. Time-lapse confocal imaging was carried out on an 248
inverted Eclipse TE2000-E microscope (Nikon, Japan) with a spinning-disk confocal scan head 249 (CSU-10; Yokogawa, Japan) mounted on the side port of the microscope and equipped with a dual 250 GFP/RFP dichroic mirror. Cells were maintained at 36.5°C on the stage and were imaged the built-251 in autofocusing system (PFS; Nikon). vGpH was excited using the 488 nm line of an argon ion laser 252 coupled into the scan head by fiber optics. Fluorescence was recorded at 515 nm with a bandpass 253 emission filter (40 nm half bandwidth) and images were captured with an Orca-Flash 4.0 CCD 254 camera (Hamamatsu Photonics, Japan) controlled by MetaMorph 7.8.6 (Molecular Devices, CA, 255 USA) at 0.5 Hz. Samples were imaged using a 60 X (NA 1.4) plan apo objective objective in 256
Tyrode's buffer (150 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 6 mM glucose, 25 mM 257 HEPES, pH 7.4) supplemented with 25 μM 6-cyano-7-nitroquinoxaline-2,3-dione / CNQX (Tocris 258 Bioscience) and 50 μM D,L-2-amino-5-phosphonovaleric acid / AP5 (Tocris Bioscience). Coverslips 259 were mounted in an RC-21BRFS chamber (Warner Instruments, USA) equipped with platinum wire 260 electrodes. Field stimulation was induced by a square pulse stimulator (Grass Technologies, USA) 261 and monitored by an oscilloscope (TDS210, Tektronix, USA). Trains of action potentials (APs) were 262 generated by applying 20 V pulses (1 ms duration) at 10 Hz. Our typical stimulation paradigm for 263 vGpH measurements involved two consecutive trains of 300 APs at 10 Hz, separated by ~5 min to 264 allow synapses to recover. vGpH responses between the first and second stimulation were highly 265 reproducible (data not shown). For measuring SV exocytic rates, the second stimulation was 266 preceded (30s earlier) by the addition of 0.5 μM Bafilomycin A1 (Baf; AG scientific, USA). To 267 normalize for total expression of vGpH in each individual bouton, 50 mM NH4Cl (membrane 268 permeable alkalinizing agent) was added at the end of the time series. 269 270
Image analysis 271
SV exo-and endocytic rates. Automated analysis of vGpH transients was previously described in 272 (19) . Briefly, responsive boutons were segmented on a ∆F image (Fpeak -Fbaseline) obtained by 273 subtracting a baseline image (before stimulation) to the image corresponding to the peak vGpH 274 response during the first stimulation (Figure 1b ). This differential analysis allowed us to use the 275 same intensity threshold across experiments. We selected a permissive image threshold (0.02%) to 276 ensure segmentation of both strongly and weakly responding boutons with ∆F/F ≥ 5% (Figure 1c ). 277
The average vGpH intensity in each segmented bouton was then computed for each time point. 278
Intensity traces were brought down to the same baseline and normalized for vGpH expression by 279 dividing them with the vGpH signal after NH4Cl addition (Figure 1d ). The MATLAB script that 280 generates these intensity traces from a single image field is available in supplementary material 281 were analyzed for each condition. Cycling parameters for each FOV are listed in Table 1  306 (Lithium_data_v53.csv, supplementary material). Boxplots were generated with Python (Jupyter 307 notebook) using the seaborn library. The box shows the quartiles (25% and 75%) of the dataset. 308
The whiskers show the rest of the distribution contained within 1.5x the IQR (interquartile range). 309
The median of the distribution is indicated by a horizontal bar. We used the Python SciPy library for 310 statistical analysis of these datasets. The nonparametric Mann-Whitney U test was employed to 311 compare SV rates (exo rates, endo rates and endo time constant post-stimulation) in control and 312 lithium-treated neurons. P values were corrected for multiple hypothesis testing using the post-hoc 313 Bonferroni method. The script (Script 3; Lithium_SV_dataset.ipynb) used to analyze these 314 aggregate data is available in supplementary material). 315 
Figure legend
